Arax Advisory Partners’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$600K Buy
10,703
+9,538
+819% +$496K ﹤0.01% 1523
2026
Q1
$56.3K Buy
1,165
+652
+127% +$28.6K ﹤0.01% 1642
2025
Q4
$19.8K Sell
513
-3,829
-88% -$146K ﹤0.01% 2117
2025
Q3
$153K Buy
4,342
+3,979
+1,096% +$144K ﹤0.01% 1366
2025
Q2
$13.1K Buy
363
+33
+10% +$1.09K ﹤0.01% 1837
2025
Q1
$10.3K Buy
330
+42
+15% +$1.33K ﹤0.01% 1562
2024
Q4
$7.35K Sell
288
-288
-50% -$7.64K ﹤0.01% 1601
2024
Q3
$16.3K Buy
576
+370
+180% +$10.2K ﹤0.01% 1170
2024
Q2
$5.43K Buy
+206
New +$5.71K ﹤0.01% 1562

Other funds holding RPRX

Arax Advisory Partners's RPRX Position: Q2 2026 in Review

Arax Advisory Partners increased its Royalty Pharma (RPRX) stake by 819% in Q2 2026, buying an estimated $496K and bringing the position to 10,703 shares worth $600K. The position accounts for ﹤0.01% of the portfolio, ranked #1523.

Arax Advisory Partners first reported a position in RPRX in Q2 2024 and has held it in 9 quarters since. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Arax Advisory Partners held 10,703 shares of Royalty Pharma worth $600K as of Q2 2026.
  • Arax Advisory Partners bought 9,538 Royalty Pharma shares in Q2 2026, an estimated $496K.
  • Royalty Pharma made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1523 holding.
  • Arax Advisory Partners first reported a position in Royalty Pharma in Q2 2024 and has held it in 9 quarters since.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.